Coronavirus disease 2019 (COVID‐19) has spread rapidly around the world since its emergence in humans last December. Previous studies suggested that numerous markers of inflammation were elevated in patients in with severe disease relative to patients with milder conditions, and an elevated level of interleukin‐6 (IL‐6) was associated with a high case fatality of COVID‐19 infection. This article is protected by copyright. All rights reserved.